Artificial Intelligence

60+ Key Companies Actively Working in the Encephalopathy Pipeline Segment | DelveInsight

Published

2 years ago

July 21, 2022

New York, USA, July 21, 2022 (GLOBE NEWSWIRE) — 60+ Key Companies Actively Working in the Encephalopathy Pipeline Segment | DelveInsight

Encephalopathy refers to dysfunction of the level or contents of consciousness due to brain dysfunction and can result from global brain insults or focal lesions. There are several different types of encephalopathies, and various companies are involved in developing the potential therapies for each type. Some of the major companies developing the therapies in different-stage of development include Xenon Pharmaceuticals, Neurocrine Biosciences, Stoke Therapeutics, Longboard Pharmaceuticals, and Praxis Precision Medicine.

DelveInsight’s ‘Encephalopathy Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline encephalopathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the encephalopathy pipeline domain.

Key Takeaways from the Encephalopathy Pipeline Report

DelveInsight’s encephalopathy pipeline report depicts a robust space with 60+ active players working to develop 70+ pipeline therapies for encephalopathy treatment.
Key encephalopathy companies such as Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, SK Biopharmaceutical, Epygenix Therapeutics, Jazz Pharmaceuticals, Vedanta Biosciences, Versantis, ReAlta Life Sciences, Cosmo Pharmaceuticals, Pharmazz, Umecrine Cognition AB, Neuropathix, DeckTherapeutics, Vittarthaa Life Sciences, Tetra Therapeutics, AC Immune, Brighton Biotech Inc., JCR Pharmaceuticals, Vyant Bio, Inc., Encoded therapeutics, Incannex, Amzell, Bio Pharm Solutions, Anavex Life Sciences, and others are evaluating novel encephalopathy drugs candidate to improve the treatment landscape.
Promising encephalopathy pipeline therapies in various stages of development include NBI-921352, XEN496, TAK-935, PRAX562, STK001, LP352, KB-3061, PRAX222, SCNA2 LoF ASO, Research programme: DEE13-SCN8A(ASO), AXA 1665, RBX 7455, ETX101, JR-031, Cannabinoid, IHL-216A, ANAVEX 2-73, CMP-SCN, ANAVEX 2-73 and others.
In June 2022, ReAlta Life Sciences announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for treating hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual action complement inhibitor and innate anti-inflammatory peptide. In March 2022, US FDA cleared an Investigational New Drug (IND) application for a Phase II clinical trial of RLS-0071.
Lead MRT drug platform product RBX2660 is targeted at treating Clostridium difficile (C.diff), ulcerative colitis, hepatic encephalopathy, and multi-drug resistant organisms. United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,433,651 to Rebiotix for its patent application entitled, “Microbiota Restoration Therapy (MRT), Compositions and Methods of Manufacture.” The patent covers Microbiota Restoration Therapy (MRT) compositions and methods for manufacturing, processing, and delivering the compositions and builds on Rebiotix’s patent issuances in Australia and Canada.
PRAX-562 is the first preferential persistent sodium channel blocker in development to treat a wide range of rare CNS disorders, including rare adult cephalgias and development and epileptic encephalopathy. In April 2021, the US FDA granted orphan drug designation to PRAX-562 for the treatment of SCN2A development and epileptic encephalopathy (SCN2A-DEE), and in January 2021, the US FDA also granted rare pediatric disease designation for PRAX-562 for the treatment of SCN2A-DEE and for the treatment of SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).
In August 2021, Vyant Bio, Inc., and Cyclica, Inc., announced a non-exclusive strategic collaboration combining Vyant Bio’s patient-derived complex organoid biology alongside Cyclica’s proteome-wide, Artificial Intelligence (“AI”) enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder (“CDD”), a severe neurodevelopmental epilepsy disorder with no effective treatments or cure.

Request a sample and discover the recent advances in encephalopathy treatment drugs @ Encephalopathy Pipeline Outlook

The encephalopathy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage encephalopathy products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the encephalopathy pipeline landscape.

Encephalopathy Overview

Encephalopathy is a broad term that refers to abnormal brain function or structure. The irregularity could be temporary, recurring, or permanent. Brain function loss can be reversible, static and steady, or progressive, with a progressive decrease of brain activity over time. Encephalopathy is classified into two types: reversible and irreversible.

The encephalopathy symptoms vary depending on the type and cause, but some of the most prevalent are confusion, memory loss, personality changes, and difficulty thinking clearly or focusing. Some people will also experience: difficulty speaking, muscle weakness or twitches, uncontrollable eye movements, tremors, and difficulty swallowing. The history provided by the patient, family, or friends is used to make an encephalopathy diagnosis. Based on the encephalopathy symptoms, the health care provider will have a better grasp of the various encephalopathy causes.

Depending on the clinical condition, imaging examinations such as X-rays, computed tomography (CT), and magnetic resonance imaging (MRI) may be relevant. Lumbar puncture (spinal tap) may be useful in detecting infection, bleeding, and inflammation. In addition, aberrant proteins, chemicals, and cells can be detected in cerebrospinal fluid. Patients with known recurring encephalopathy may be eligible for home encephalopathy treatment programs.

Find out more about encephalopathy drugs @ Encephalopathy Treatment Drugs

A snapshot of the Encephalopathy Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
XEN496	Xenon Pharmaceuticals	Phase III	GABA A receptor agonists; KCNQ potassium channel agonists	Oral
AXA 1665	Axcella Health	Phase II	Metabolism-modulators	Oral
RBX 7455	Rebiotix	Phase II	Bacteria replacements; Gastrointestinal microbiome modulators	Oral
NBI-921352	Neurocrine Biosciences	Phase II	Nav1.6 voltage-gated sodium channel inhibitors	Oral
STK-001	Stoke Therapeutics	Phase II	NAV1.1 voltage-gated sodium channel modulators; RNA interference	Intrathecal
LP352	Longboard Pharmaceuticals	Phase I/II	Serotonin 2C receptor agonists	Oral
KB-3061	Knopp Bioscience	Preclinical	KCNQ2 potassium channel stimulants	Oral

Learn more about the novel and emerging encephalopathy pipeline therapies @ Encephalopathy Clinical Trials

Encephalopathy Therapeutics Assessment

The encephalopathy pipeline report proffers an integral view of the encephalopathy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Encephalopathy Pipeline Report

Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
Therapeutics Assessment By Mechanism of Action: GABA A receptor agonists, KCNQ potassium channel agonists, Metabolism-modulators, Bacteria replacements, Gastrointestinal microbiome modulators, Nav1.6 voltage-gated sodium channel inhibitors, Cholesterol 24-hydroxylase inhibitors, NMDA receptor modulators, Sodium channel antagonists
Key Encephalopathy Companies: Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, SK Biopharmaceutical, Epygenix Therapeutics, Jazz Pharmaceuticals, Vedanta Biosciences, Versantis, ReAlta Life Sciences, Cosmo Pharmaceuticals, Pharmazz, Umecrine Cognition AB, Neuropathix, DeckTherapeutics, Vittarthaa Life Sciences, Tetra Therapeutics, AC Immune, Brighton Biotech Inc., JCR Pharmaceuticals, Vyant Bio, Inc., Encoded therapeutics, Incannex, Amzell, Bio Pharm Solutions, Anavex Life Sciences and others
Key Encephalopathy Pipeline Therapies: NBI-921352, XEN496, TAK-935, PRAX562, STK001, LP352, KB-3061, PRAX222, SCNA2 LoF ASO, Research programme: DEE13-SCN8A(ASO), AXA 1665, RBX 7455, ETX101, JR-031, Cannabinoid, IHL-216A, ANAVEX 2-73, CMP-SCN, ANAVEX 2-73 and others.

Dive deep into rich insights for drugs for encephalopathy treatment, visit @ Encephalopathy Treatment

Table of Contents

1.	Encephalopathy Pipeline Report Introduction
2.	Encephalopathy Pipeline Report Executive Summary
3.	Encephalopathy Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Encephalopathy Pipeline Therapeutics
6.	Encephalopathy Pipeline: Late Stage Products (Pre-registration)
7.	Encephalopathy Pipeline: Late Stage Products (Phase III)
7.1	XEN496: Xenon Pharmaceuticals
8.	Encephalopathy Pipeline: Mid Stage Products (Phase II)
8.1	AXA 1665: Axcella Health
9.	Encephalopathy Pipeline: Early Stage Products (Phase I/II)
9.1	LP352: Longboard Pharmaceuticals
10.	Encephalopathy Pipeline Therapeutics Assessment
11.	Inactive Products in the Encephalopathy Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Encephalopathy Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the encephalopathy pipeline therapeutics, reach out @ Encephalopathy Drugs

Developmental and Epileptic Encephalopathies Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key developmental and epileptic encephalopathies companies including Novartis, Roche, Lundbeck, among others.

Developmental and Epileptic Encephalopathies Epidemiology Forecast

Developmental and Epileptic Encephalopathies Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted developmental and epileptic encephalopathies epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Developmental and Epileptic Encephalopathies Pipeline
Developmental and Epileptic Encephalopathies Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key developmental and epileptic encephalopathies companies, including Novartis, Roche, Lundbeck, among others.

Hepatic Encephalopathy Pipeline

Hepatic Encephalopathy Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hepatic encephalopathy companies, including Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, among others.

Overt Hepatic Encephalopathy Pipeline

Overt Hepatic Encephalopathy Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key overt hepatic encephalopathy companies, including Knoop Biosciences, Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, among others.

Chronic Traumatic Encephalopathy Pipeline

Chronic Traumatic Encephalopathy Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic traumatic encephalopathy companies, including Tetra Therapeutics, Brighton Biotech, among others.

Other Trending Reports

Related Healthcare Blogs

Developmental and Epileptic Encephalopathies Treatment Pipeline
Epidiolex vs Fintepla
Hepatic Encephalopathy Market Dynamics

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.

Connect with us at LinkedIn

Related Topics:AI Artificial Intelligence Machine learning

Up Next

OTC: DRCR, Swifty Global (Dear Cashmere Holding Company) Announces the Launch of Its Swifty Predictions App in the United Kingdom

Don't Miss

Stolen Credentials Selling on the Dark Web for Price of a Gallon of Gas

GlobeNewswire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

sCrypt Launches Chain-Agnostic Developer Platform for UTXO Blockchains

Published

52 mins ago

July 1, 2024

CISION (PR Newswire)

SAN FRANCISCO, July 1, 2024 /PRNewswire/ — sCrypt, a full-stack Web3/blockchain development platform, has announced the launch of its groundbreaking developer tool kit designed for the Unspent Transaction Output (UTXO) blockchains. The new tools will revolutionise how developers interact with UTXO blockchains, making them more accessible and fostering creativity in the Web3 space.

UTXO is the method the Bitcoin protocol uses to track balances as they move between digital wallets. The UTXO model is essential for maintaining the security and integrity of blockchain networks and solves the double-spend problem.
The sCrypt platform provides comprehensive toolkits such as Software Development Kits (SDK) and Application Programming Interfaces (APIs) that allow developers to seamlessly integrate UTXO blockchains into their applications. The platform will also integrate a vast ecosystem of JavaScript/TypeScript developers, estimated at 13 million globally. These developers can now leverage their existing skills to build and operate on UTXO blockchains.
By doing so, sCrypt opens a world of opportunities, where developers are equipped with the best tools to drive innovation and success.
The SDK provides libraries in various languages, detailed documentation, and tutorials and offer a flexible and robust framework for leveraging payments, tokens, and smart contracts. Whereas APIs allow developers to read from and write into blockchains, without setting up and maintaining their own nodes and indexers. As a tool kit, they allow developers to focus on the business logic of their dApp (decentralised applications), rather than worrying about the underlying blockchain infrastructure.
The platform is chain-agnostic, allowing developers to focus all their intellectual horsepower on application development rather than blockchain specifics. This industry-first platform is designed to power Web3 growth and empower developers to build and scale their dApp efficiently and effortlessly, by leveraging UTXO’s unparalleled scalability and programmability.
Xiaohui Liu, Founder and CEO at sCrypt said, “Historically, Web3 applications have been largely built on account-based blockchains like Ethereum and Solana. Ordinals have brought renewed development interest back to Bitcoin and UTXO blockchains. With our extensive developer tooling and infrastructure, it is now easier than ever to build on UTXO blockchains, empowering builders to unleash UTXO’s superior scalability and programmability.”
Companies utilising the sCrypt platform include BTC platforms, such as Dotswap, the first BRC20 token swap platform on BTC, offer fast and seamless token exchanges, leveraging a fully functioning Automated Market Maker (AMM) and liquidity pools. It uses sCrypt’s APIs to query the status of tokens, including BRC20 and Runes. TierTopis another cutting-edge BTC trading platform that supports Ordinals NFTs, BRC-20 tokens, and bitmaps which rely on sCrypt’s token APIs.
Other businesses using sCrypt include Tokenovate, which leverages sCrypt’s smart contracts to manage trading lifecycle events of derivatives, such as interest-rate swaps and voluntary carbon credits. Additionally, various innovative applications benefiting from sCrypt’s toolkit are Hodlocker, Order Lock by RelayX, Tokenized, 1Sat Ordinals and Yours Wallet.
The sCrypt platform is poised to be a game-changer for developers working within the UTXO framework, offering them resources to develop next-generation blockchain applications and aiming to become the de-facto development platform for UTXO blockchains.
About sCrypt:sCrypt is a UTXO-blockchain development platform that offers a suite of tools and infrastructure to enhance and accelerate the development process of decentralised applications (dApps). It provides a rich set of APIs and software development kits (SDKs) that simplify blockchain interactions, such as querying blockchain data, sending transactions, issuing tokens, and developing smart contracts. It specialises in UTXO blockchains and supports multiple of them, such as Bitcoin and Bitcoin SV.

View original content:https://www.prnewswire.co.uk/news-releases/scrypt-launches-chain-agnostic-developer-platform-for-utxo-blockchains-302186804.html

Artificial Intelligence

ALLATRA President Discussed Climate Change with Pope Francis

Published

52 mins ago

July 1, 2024

CISION (PR Newswire)

allatra-president-discussed-climate-change-with-pope-francis

The Pope received the President of ALLATRA in an audience at the Vatican
VATICAN CITY, July 1, 2024 /PRNewswire/ — Pope Francis hosted distinguished scientists and experts from various countries and disciplines at a private audience at the Apostolic Palace in Vatican City. The selected attendees were participants in the Three-day International Conference on ‘Generative Artificial Intelligence and Technocratic Paradigm,’ organized by the Centesimus Annus Pro Pontifice Foundation (CAPP) – operating within the Secretariat of State of the Holy See and led by the esteemed Chairwoman, Dr. Anna Maria Tarantola.

Among the invited guests were Dr. A. Egon Cholakian, a National Security Expert, Washington D.C. Governmental Affairs Advisor to the ALLATRA International Public Movement, CAPP Foundation member; and Maryna Ovtsynova, President of the ALLATRA International Public Movement.
During the audience at the Vatican, the President of ALLATRA presented to Pope Francis a climate report ‘On The Progression Of Climatic Disasters On Earth And Their Catastrophic Consequences.’ In their personal conversation, she raised the issue of climate change as a global problem, emphasizing that it represents one of the most pressing challenges for humanity.
During the conversation, Pope Francis listened attentively and expressed his pleasure in offering his blessing to the ALLATRA International Public Movement. Following the event, Maryna Ovtsynova, President of ALLATRA, also personally received a blessing from the Holy See and Pope Francis on this significant day for the ALLATRA organization.
Additionally, the international conference featured discussions on technological innovations that are set to shape the future of civilization.
Since the future of humanity will be played out on the front of technological innovation, Pope Francis stated, “We must not miss the opportunity to think and act in a new way, with mind, heart and hands,” in order to “direct innovation toward a configuration centred on the primacy of human dignity.” – cites ‘Vatican News.’
During the event, in a pivotal discussion with conference organizers, Maryna Ovtsynova, President of the ALLATRA International Public Movement, addressed the pressing global threats to freedom and democracy. Mrs. Ovtsynova addressed the ongoing investigation into the illegal persecution of ALLATRA participants in several countries with low democracy indexes. Specifically, she detailed how they were subjected to a defamation campaign initiated by a Russian anti-cult organization. Additionally, she mentioned that this defamation campaign occurred not only in Russia but also in Ukraine, which indicates the significant influence of the Russian anti-cult organization on Ukraine.
During the conversation, Maryna Ovtsynova also raised the issue that anti-cult organizations, which exist contrary to democratic norms, cast a shadow on faith and on what Christianity stands for—freedom of religion and freedom of conscience.
During an audience on June 22, 2024, Maryna Ovtsynova expressed heartfelt gratitude to Pope Francis for his significant contributions as a responsible and decisive leader in the social integration of the Roman Catholic Church and for strengthening its role in contemporary secular society. She also thanked him for his kindness, warmth, and support during this special moment for ALLATRA.
Photo – https://mma.prnewswire.com/media/2451854/ALLATRA_Pope_Francis_Maryna_Ovtsynova.jpgPhoto – https://mma.prnewswire.com/media/2451855/Vatican_ALLATRA_collage.jpg

View original content:https://www.prnewswire.co.uk/news-releases/allatra-president-discussed-climate-change-with-pope-francis-302186790.html

Artificial Intelligence

35 Institutions Recognised for Excellence in Education and Innovation in the 2024 Anthology Catalyst Awards

Published

52 mins ago

July 1, 2024

CISION (PR Newswire)

35-institutions-recognised-for-excellence-in-education-and-innovation-in-the-2024-anthology-catalyst-awards

BOCA RATON, Fla., July 1, 2024 /PRNewswire/ — Anthology, the leading provider of education solutions that support the entire learner lifecycle, today announced the winners of the 2024 Catalyst Awards. The awards honour those driving innovation and excellence within higher education. Winners are recognised across 8 categories and selected by a cross-functional team of Anthology experts and represent the very best in their field.

This year, 35 winners were selected from among 108 nominees from institutions across 19 countries. Honourees will be recognised at the upcoming Anthology Together conference, one of the world’s largest EdTech conferences, taking place July 15-17 in Orlando, Florida.
“The Catalyst Awards celebrate what’s at the heart of higher education and technology – working together to drive student success. It’s inspiring to see the creative programmes and remarkable outcomes,” said Bruce Dahlgren, Chief Executive Officer at Anthology. “I am personally honoured to work with such an incredible community of innovators and educators as we partner together to deliver bold solutions to meet the needs of students and those who support them.”
The 2024 Anthology Catalyst Award winners by category:
Assessment & Institutional Effectiveness: This award recognises institutions that have successfully grown in their assessment practices and influenced positive behavioural changes using Anthology solutions.
Keiser University – Online Division, United States of America: The Online Academic Team – Sherry Olsen, Neha Prakash, and Marcel LarondeOdessa College, United States of America: Institutional Effectiveness Division – Connie MayUniversity of Cincinnati, United States of America: Traci SteehlerUniversity of the District of Columbia, United States of America: The Center for the Advancement of Learning & The Office of Planning and Institutional EffectivenessDiversity, Equity, Inclusion, and Belonging: This award honours those institutions leveraging technology to foster diversity, equity, inclusion, and belonging practices using Anthology solutions to ensure that their services are fully inclusive and supportive of all learners.
Grupo Ser Educacional, Brazil: EaD Management – Janyo Diniz, Joaldo Diniz, Enzo Moreira, Francislene Hasmann, and Sergio MuriloUniversity of Bahrain, Kingdom of Bahrain: Dr. Mazen AliUniversity of Derby, United Kingdom: PLT: Digital Learning and Online Content TeamUniversity of Illinois Chicago, United States of America: Landen DixonInstitutional Advancement: This award recognises institutions that have made significant changes to enhance the alumni and donor experience using Anthology solutions.
Morehead State University, United States of America: Alumni Relations & Development: Jessi Ferguson, Allie Rayburn, and Sherry SurmontUniversity of Louisville, United States of America: Communications & Marketing – Jessica Watts and Natalie TracyUniversity of Washington, United States of America: University AdvancementLeading Change: This award recognises institutions at the forefront of educational innovation that have used Anthology solutions to implement transformational initiatives that generate change on campus and in their academic ecosystems, with measurable results.
Central Michigan University, United States of America: The Office of Curriculum and Instructional Support – Marnie RoestelGrand Valley State University, United States of America: GVSU eLearning TechnologiesNorthumbria University, University of Southampton, College of DuPage, and WSU Tech, United Kingdom and United States of America. International Ally User Group: Kristen McCartney-Bulmer, Northumbria University; Matthew Deeprose, University of Southampton; Krystal Iseminger, WSU Tech; and Lara Tompkins, College of Du PageImam Abdulrahman Bin Faisal University, Kingdom of Saudi Arabia: Deanship of eLearning and Distance Learning – Dr. Muneerah B. AlmahasheerMapúa Malayan Colleges Laguna, Philippines: Mapúa Laguna 4Cers – Dr. Dodjie S. Maestrecampo, Anthony Hilmer S. Medrano, Maribel G. Songsong, Dr. Ramachandra C. Torres, Christian Dominic V. Kare, and John Mark L. AlmarezStudent Experience: This award recognises institutions leveraging technology to develop educational and administrative innovations that positively influence the total learner experience – outside and inside the classroom – and improve operational efficiency.
California Polytechnic State University, United States of America: Division of Student AffairsEdge Hill University, United Kingdom: Learning Design and Student Life TeamsMarshall University, United States of America: Enrollment Management – Dr. Jerry Ross, Dr. Beverly Boggs, and Nathan MillerSam Houston State University, United States of America: Student Involvement – Dr. Meredith Conrey and Emily FigueroaThe University of Memphis, United States of America: Dr. MK TylerStudent Success: This award recognises institutions whose innovative use of Anthology solutions has led to increased retention, increased completion, or improved outcomes through the implementation of new academic and administrative resources, data analytics solutions, scalable advising and intervention strategies and student support programmes.
Bellevue University, United States of America: College of Engineering, Technology and Management – Dr. Matthew Davis, Rebecca Barnes, and Nathan KraftJenison Innovation Academy (JIA), United States of America: JIA Leadership Team – Cameron Kuiper, Dr. Rebekah Redmer, and Krista OsterbergNorthern Border University, Kingdom of Saudi Arabia: Deanship of E-Learning and Knowledge Resources – Dr. Saud Abdul Mohsen Al-Muqahim, Dr. Sultan Munadi Al-Anazi, and Dr. Ghanim Tawash AlAnaziUniversity of Florida, George Mason University, and University of North Carolina at Charlotte, United States of America: Shared Metacognition Team: Dr: Larisa Olesova, University of Florida; David Miller, George Mason University; and Dr. Ayesha Sadaf, University of North Carolina CharlotteTeaching & Learning: This award recognises institutions that have used Anthology solutions in innovative ways to advance learning.
Beacon Red, United Arab Emirates: Knowledge Systems Team – Phil Burgess, Sean McGuinness, Anurag Patel, and Jimmy JosephTechnical and Vocational Training Corporation, Kingdom of Saudi Arabia: E-Learning Center – Abdullah Farhan Aljably and Abdullah AldukhayyelThe University of Texas at El Paso, United States of America: The Center for Instructional DesignUniversidad Abierta Interamericana, Argentina: Faculty of Information Technology – Dr. Marcelo Edgardo De Vincenzi Zemborain, Nicolás Battaglia, and Dr. Carlos NeilWestern Kentucky University, United States of America: IDST 100 Course Development Team – Catie Weaver, Alicia Pennington, Ara Sprouse, and Brittney SholarTraining & Professional Development: This award recognises institutions that display an organisation-wide dedication to innovative training and development programmes for their educators and staff.
William Paterson University, United States of America: The Center for Teaching with Technology – Dr. Jae KimUniversidad Peruana de Ciencias Aplicadas, Peru: Diseño de entornos de aprendizaje DEA – DADO Team – Jessica Vlasica, Milagros Suyo, and Nancy OlmosUniversity of Central Oklahoma, United States of America: Center for eLearning and Connected Environments – Darren DenhamUniversity of Pretoria, South Africa: E-Education GroupWichita State University, United States of America: Office of Instructional ResourcesFor more information on the 2024 Catalyst Award winners, the full list of nominees, and complete category descriptions, please visit www.anthology.com/catalystawards.
About Anthology
Anthology offers the largest EdTech ecosystem on a global scale for education, supporting more than 150 million users in 80 countries. With a mission to provide dynamic, data-informed experiences to the global education community through Anthology Intelligent Experiences™, we help learners, leaders and educators achieve their goals by offering over 60 SaaS products and services designed to advance learning. Discover more about how we are fulfilling our mission for education, business and government institutions at www.anthology.com.
Media Contact: Erin Mitchell, Director of Communications, Anthology. [email protected]
Logo – https://mma.prnewswire.com/media/1708867/Anthology_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/35-institutions-recognised-for-excellence-in-education-and-innovation-in-the-2024-anthology-catalyst-awards-302186250.html